Genmab, a biotech firm, is receiving mixed reviews from analysts and investors. Its stocks are viewed as promising by some, citing the company’s
share buy-back program instilling confidence in the board's outlook. Similarly,
H.C. Wainwright and
Truist maintain a buy rating with respective price targets of $37 and $50. Analysts also lauded
Genmab's strong market position and growth potential, with the company reporting $3 billion Darzalex sales for Q1 2025. However, setbacks such as J&J's decision not to exercise the option on HexaBody-CD38 and the lawsuit with AbbVie triggered concerns. Despite these challenges, the company is being recognised as
potentially undervalued, with its share buy-back program and Darzalex sales contributing to a positive outlook for Genmab's 2025 performance. Yet, the firm’s performance in 2024 was perceived as worse among biotech stocks, and
Darzalex sales and the containment of shares has raised questions about the company's future. While Genmab is facing hurdles, its proactive measures and robust financial performance suggest potential for recovery and growth.
Genmab Stocks News Analytics from Tue, 20 Aug 2024 07:00:00 GMT to Fri, 25 Apr 2025 18:56:54 GMT -
Rating 5
- Innovation -3
- Information 2
- Rumor -4
